title: Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis.
abstract: A total of 165 patients with disseminated Lyme borreliosis (diagnosed in 1990-94, all seropositive except one culture-positive patient) were followed after antibiotic treatment, and 32 of them were regarded as having a clinically defined treatment failure. Of the 165 patients, 136 were tested by polymerase chain reaction (PCR) during the follow-up. PCR was positive from the plasma of 14 patients 0-30 months after discontinuation of the treatment, and 12 of these patients had a clinical relapse. In addition, Borrelia burgdorferi was cultured from the blood of three patients during the follow-up. All three patients belonged to the group with relapse, and two of them were also PCR positive. This report focuses on the 13 patients with clinical relapse and culture or PCR positivity. Eight of the patients had culture or PCR-proven initial diagnosis, the diagnosis of the remaining five patients was based on positive serology only. All 13 patients were primarily treated for more than 3 months with intravenous and/or oral antibiotics (11 of them received intravenous ceftriaxone, nine for 2 weeks, one for 3 weeks and one for 7 weeks, followed by oral antibiotics). The treatment caused only temporary relief in the symptoms of the patients. All but one of them had negative PCR results immediately after the first treatment. The patients were retreated usually with intravenous ceftriaxone for 4-6 weeks. None of them was PCR positive after the retreatment. The response to retreatment was considered good in nine patients. We conclude that the treatment of Lyme borreliosis with appropriate antibiotics for even more than 3 months may not always eradicate the spirochete. By using PCR, it is possible to avoid unnecessary retreatment of patients with 'post-Lyme syndrome' and those with 'serological scars' remaining detectable for months or years after infection.
authors.affiliation: Department of Medicine, Turku University Central Hospital, Finland. jarmo.oksi@utu.fi
authors.forename: J
authors.initials: J
authors.lastname: Oksi
authors.forename: M
authors.initials: M
authors.lastname: Marjamäki
authors.forename: J
authors.initials: J
authors.lastname: Nikoskelainen
authors.forename: M K
authors.initials: MK
authors.lastname: Viljanen
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D000936:Antigen-Antibody Complex; D015748:Borrelia burgdorferi Group / Q000302:isolation & purification*; D001921:Brain / Q000473:pathology; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D012008:Recurrence; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D000936:Antigen-Antibody Complex